Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSPC PHARMA

6.150
+0.1001.65%
Volume:183.22M
Turnover:1.13B
Market Cap:71.00B
PE:15.66
High:6.310
Open:6.060
Low:6.060
Close:6.050
Loading ...

CSPC Pharmaceutical Sees Decrease in Profit Attributable for Year of 26%

THOMSON REUTERS
·
25 Feb

CSPC Pharmaceutical - Expected Result Due to Decrease in Revenue of Finished Drugs Business for Year

THOMSON REUTERS
·
25 Feb

Radiance Biopharma Enters Exclusive License for Ror-1 Targeted Antibody Drug Conjugate

THOMSON REUTERS
·
20 Feb

CSPC Pharmaceutical Group's Subsidiary Signs Exclusive Licensing Agreement for Cancer Drug

MT Newswires Live
·
19 Feb

BRIEF-CSPC Pharmaceutical Receives Exclusive License Agreement For SYS6005 With Radiance Biopharma

Reuters
·
19 Feb

CSPC Pharmaceutical - Exclusive License Agreement for Sys6005 With Radiance Biopharma

THOMSON REUTERS
·
19 Feb

CSPC Pharmaceutical - CSPC Megalith Will Receive Upfront Payments of US$15 Mln

THOMSON REUTERS
·
19 Feb

CSPC Pharmaceutical's Unit Gets China Nod for Marketing of New Indication of Asthma Drug

MT Newswires Live
·
11 Feb

BRIEF-Cspc Pharmaceutical Says Syh2059 Tablets Obtains Clinical Trial Approval In U.S.

Reuters
·
10 Feb

BRIEF-Cspc Pharmaceutical Says Enyitan Obtains Marketing Approval By Nmpa

Reuters
·
10 Feb

CSPC Pharmaceutical - New Indication for Enyitan Obtains Marketing Approval by Nmpa

THOMSON REUTERS
·
10 Feb

CSPC Pharmaceutical - Syh2059 Tablets Obtains Clinical Trial Approval in U.S. by US FDA

THOMSON REUTERS
·
10 Feb

CSPC Pharmaceutical Group Limited's (HKG:1093) Share Price Not Quite Adding Up

Simply Wall St.
·
10 Feb

CSPC Pharmaceutical Get China Nod for Herpes Zoster Drug Trial

MT Newswires Live
·
07 Feb

BRIEF-CSPC Pharmaceutical Says Sys6017 Obtained Clinical Trial Approval From NMPA

Reuters
·
07 Feb

CSPC Pharmaceutical - Sys6017 (Herpes Zoster Mrna Vaccine) Obtains Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
07 Feb

CSPC Pharmaceutical Gets China Nod for Registration of Tumor Drug

MT Newswires Live
·
21 Jan

BRIEF-Cspc Pharmaceutical Says Regorafenib Tablets Obtains Drug Registration Approval

Reuters
·
20 Jan

CSPC Pharmaceutical - Regorafenib Tablets Obtains Drug Registration Approval From Nmpa China

THOMSON REUTERS
·
20 Jan

BRIEF-CSPC Pharmaceutical Says Sys6043 Obtains Clinical Trial Approval

Reuters
·
16 Jan